Discover how a groundbreaking cognitive assessment tool is transforming early dementia detection with 99.9% accuracy and what ...

More than six million Americans age 65 and up are living with Alzheimer’s including more than 35,000 Nebraska residents.

Anavex Life Sciences shares were up 7% to $11.25 after the company said it saw positive trial results for its oral blarcamesine for the treatment of early Alzheimer's disease. The clinical-stage ...

Activation of SIGMAR1 is expected to restore cellular homeostasis by inducing autophagy, which may slow neurodegeneration in patients with early AD.

A breakthrough study highlights Xenon gas as a potential game-changer in treating Alzheimer’s disease, demonstrating its ...

The risk of developing dementia may be double what was previously thought. But there are things the U.S. can do to help fight ...

In a trial featuring a mouse model of Alzheimer's, scientists found that inhaling a mixture containing xenon gas helped ...

The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...

Cognitive profiles for early diagnosis of Dementia with Lewy bodies (DLB) have been outlined in a new study. Although DLB is the second most common neurodegenerative dementia following Alzheimer's ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Most treatments being pursued today to protect against Alzheimer's disease focus on amyloid plaques and tau tangles that ...